Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Resolv ER may remedy leading causes of blindness in adults
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Subscribe To Our Newsletter & Stay Updated
